At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 807 enrolled
Drug / intervention
mRNA-1975 +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2, Randomized, Observer-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Immunogenicity of Heptavalent mRNA-1975 (SR1-7) and Monovalent mRNA-1982 (SR1) in Parallel Against Lyme Disease in Healthy Participants 18 Through 70 Years of Age
In Brief
A Phase 2 clinical trial evaluating mRNA-1975, mRNA-1982, and 1 other intervention for Lyme Disease. Completed, enrolled 807 participants across 20 sites.
Detailed Summary
The purpose of this study is to evaluate the safety and immunogenicity in parallel of heptavalent mRNA-1975 and monovalent mRNA-1982 against Lyme disease in healthy adult participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLyme Disease
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202420252026
Enrollment StartJul 2023
First PostedAug 2023
Primary CompletionMay 2025
TodayJul 2026
First PostedAug 3, 2023
Enrollment StartJul 26, 2023
Primary CompletionMay 30, 2025
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 2.9 years ago
Interventions
mRNA-1975biological
Dispersion delivered IM
mRNA-1982biological
Dispersion delivered IM
Placebobiological
Solution delivered IM